October 8, 2018

Humanetics Corporation Invited to Present Data on BIO 300 at Government Conference

Presentation will share data about BIO 300 and its regulatory path to FDA approval.

 

MINNEAPOLIS, MN — Humanetics Corporation (Humanetics) has been invited to present data about its drug, BIO 300, at a conference hosted by the National Institute of Allergies and Infectious Disease being held October 9^th and 10^th in Rockville, MD.  The conference organizing committee invited speakers from industry and government agencies, who are coming together to discuss the FDA approval process for new drugs related to radiation injury.  Mr. John Dykstra, Chief Operating Officer at Humanetics, will present data related to Humanetics’ new drug candidate, BIO 300.

The ongoing development of BIO 300 is based upon research initiated by the U.S. Department of Defense in its efforts to discover medical countermeasures against radiation injury. The drug is being developed to protect both military personnel and civilians from the harmful effects of radiation exposure resulting from radiological and nuclear incidents.  BIO 300 is one of the most advanced drugs under development and has been supported with funding from multiple federal agencies.

BIO 300 is also being developed by Humanetics as a supportive care product to limit the side-effects associated with radiation treatment for various cancers.  It is currently being studied in a Phase 1b/2a clinical trial in patients with non-small cell lung cancer.

About Humanetics Corporation

Humanetics Corporation is a clinical-stage specialty pharmaceutical company engaged in the accelerated discovery, development and commercialization of proprietary drugs in markets with urgent and unmet needs, with a focus on radiation modulators for oncology and medical countermeasure uses.

For more information, visit www.humaneticscorp.com.